{"id":26806,"date":"2025-06-24T15:24:23","date_gmt":"2025-06-24T12:24:23","guid":{"rendered":"https:\/\/www.clinica-sante.com\/ro\/analize-fara-categorie\/panel-genetic-somatic-cancer-colon-din-biopsie-lichida-14-gene\/"},"modified":"2026-06-19T18:26:23","modified_gmt":"2026-06-19T15:26:23","slug":"panel-genetic-somatic-cancer-colon-din-biopsie-lichida-14-gene","status":"publish","type":"product","link":"https:\/\/www.clinica-sante.com\/ro\/analize-oncogenetica\/panel-genetic-somatic-cancer-colon-din-biopsie-lichida-14-gene\/","title":{"rendered":"Panel genetic somatic cancer colon din biopsie lichida"},"content":{"rendered":"

Panelul pentru cancer de colon din biopsie lichid\u0103 este o investiga\u021bie molecular\u0103 avansat\u0103 bazat\u0103 pe tehnologia NGS (Next Generation Sequencing)<\/strong>, care permite analiza muta\u021biilor somatice din ADN-ul tumoral circulant (ctDNA) extras din s\u00e2nge periferic.<\/p>\n

Testul este utilizat \u00een cancerul colorectal pentru identificarea unor alter\u0103ri genetice cu impact direct asupra deciziilor terapeutice, prognosticului \u0219i monitoriz\u0103rii r\u0103spunsului la tratament. Analiza permite detectarea muta\u021biilor hotspot, a inser\u021biilor\/dele\u021biilor, a varia\u021biilor de num\u0103r de copii \u0219i a altor modific\u0103ri genetice implicate \u00een oncogenez\u0103 \u0219i rezisten\u021b\u0103 la tratament.<\/p>\n

Sunt evaluate gene frecvent implicate \u00een cancerul de colon, precum KRAS, NRAS, BRAF, PIK3CA, APC, TP53, SMAD4, EGFR<\/strong>, precum \u0219i alte gene relevante clinic implicate \u00een c\u0103ile de semnalizare tumoral\u0103 \u0219i reparare ADN.<\/p>\n

Biopsia lichid\u0103 ofer\u0103 o imagine dinamic\u0103 a heterogenit\u0103\u021bii tumorale \u0219i permite monitorizarea \u00een timp real a apari\u021biei clonelor rezistente, f\u0103r\u0103 necesitatea unei biopsii tisulare repetate.<\/p>\n

Indica\u021bii de testare<\/h3>\n
    \n
  • Cancer colorectal (colon sau rect) confirmat histopatologic<\/li>\n
  • Boal\u0103 metastatic\u0103 sau local avansat\u0103<\/li>\n
  • Alegerea terapiei personalizate (terapii \u021bintite)<\/li>\n
  • Monitorizarea r\u0103spunsului la tratament oncologic<\/li>\n
  • Detectarea mecanismelor de rezisten\u021b\u0103 la terapie<\/li>\n
  • Suspiciune de progresie sau recuren\u021b\u0103 tumoral\u0103<\/li>\n
  • Material tumoral insuficient pentru testare molecular\u0103 din biopsie tisular\u0103<\/li>\n
  • Reevaluare molecular\u0103 \u00een cursul evolu\u021biei bolii<\/li>\n
  • Evaluare pentru includere \u00een studii clinice<\/li>\n<\/ul>\n

    Cui se adreseaz\u0103<\/h3>\n
      \n
    • Pacien\u021bilor cu cancer colorectal diagnosticat<\/li>\n
    • Pacien\u021bilor afla\u021bi \u00een tratament oncologic sistemic<\/li>\n
    • Pacien\u021bilor cu boal\u0103 metastatic\u0103<\/li>\n
    • Pacien\u021bilor la care biopsia tisular\u0103 nu este posibil\u0103 sau suficient\u0103<\/li>\n
    • Medicilor oncologi \u0219i gastroenterologi implica\u021bi \u00een managementul cancerului colorectal<\/li>\n
    • Pacien\u021bilor care necesit\u0103 monitorizare molecular\u0103 dinamic\u0103<\/li>\n<\/ul>\n

      Metodologie de testare<\/h3>\n
        \n
      • Biopsie lichid\u0103 din s\u00e2nge periferic<\/li>\n
      • Izolarea ADN-ului tumoral circulant (ctDNA<\/strong>) din plasm\u0103<\/li>\n
      • Secven\u021biere de nou\u0103 genera\u021bie (NGS<\/strong>)<\/li>\n
      • Detectarea:\n
          \n
        • muta\u021biilor punctiforme (SNV)<\/li>\n
        • inser\u021biilor \u0219i dele\u021biilor (Indels)<\/li>\n
        • varia\u021biilor de num\u0103r de copii (CNV)<\/li>\n<\/ul>\n<\/li>\n
        • Analiz\u0103 bioinformatic\u0103 \u0219i interpretare clinic\u0103<\/li>\n
        • Corelare cu ghiduri oncologice interna\u021bionale pentru cancer colorectal<\/li>\n<\/ul>\n

          Gene analizate (relevan\u021b\u0103 clinic\u0103 \u00een cancer colorectal)<\/h3>\n

          \u00cen cancerul colorectal se analizeaz\u0103 gene precum:<\/h3>\n

          KRAS,\u00a0NRAS,\u00a0BRAF,\u00a0PIK3CA,\u00a0APC,\u00a0TP53,\u00a0SMAD4,\u00a0EGFR,\u00a0FBXW7,\u00a0CTNNB1,\u00a0AKT1,\u00a0GNAS.<\/h3>\n

          Beneficii \u0219i importan\u021b\u0103 clinic\u0103<\/h3>\n
            \n
          • Permite evaluarea molecular\u0103 minim invaziv\u0103 a cancerului colorectal<\/li>\n
          • Identific\u0103 muta\u021bii genetice care pot influen\u021ba alegerea tratamentului<\/li>\n
          • Ajut\u0103 la alegerea tratamentului \u021bintit personalizat<\/li>\n
          • Detecteaz\u0103 precoce mecanismele de rezisten\u021b\u0103 la tratament<\/li>\n
          • Ofer\u0103 informa\u021bii despre heterogenitatea tumoral\u0103<\/li>\n
          • Permite monitorizarea dinamic\u0103 a profilului molecular tumoral pe parcursul evolu\u021biei bolii<\/li>\n
          • \u00cen anumite cazuri, poate eviden\u021bia modific\u0103ri moleculare \u00eenaintea progresiei imagistice<\/li>\n
          • Poate reduce necesitatea biopsiilor tisulare repetate<\/li>\n<\/ul>\n

            Analize asociate recomandate<\/h3>\n

            Investiga\u021bii anatomopatologice<\/h3>\n
              \n
            • Examen histopatologic tumoral<\/li>\n
            • Imunohistochimie<\/li>\n
            • MSI (Microsatellite Instability)<\/li>\n
            • MMR (MLH1, MSH2, MSH6, PMS2)<\/li>\n<\/ul>\n

              Teste moleculare complementare<\/h3>\n
                \n
              • Panel NGS tumoral din \u021besut (FFPE)<\/li>\n
              • Cancer Comprehensive NGS Panel<\/li>\n
              • Testare RAS extended (KRAS\/NRAS)<\/li>\n
              • BRAF V600E<\/li>\n
              • Testare germinal\u0103 pentru sindrom Lynch (MLH1, MSH2, MSH6, PMS2)<\/li>\n
              • HRD \/ alte markere de instabilitate genomic\u0103 (\u00een cazuri selectate)<\/li>\n<\/ul>\n

                Monitorizare oncologic\u0103<\/h3>\n
                  \n
                • CT \/ RMN \/ PET-CT<\/li>\n
                • Markeri tumorali (CEA, CA 19-9)<\/li>\n
                • Evaluare oncologic\u0103 periodic\u0103<\/li>\n<\/ul>\n

                  Prob\u0103 recoltat\u0103 \/ condi\u021bii analiz\u0103<\/h3>\n

                  S\u00e2nge venos periferic<\/h3>\n

                  Tub Streck (Cell-Free DNA Collection Tube)<\/h3>\n
                    \n
                  • Recoltare \u00eenainte sau \u00een cursul tratamentului oncologic, conform indica\u021biei medicului<\/li>\n
                  • Transport conform condi\u021biilor pentru conservarea ctDNA<\/li>\n<\/ul>\n

                    Documente obligatorii<\/h3>\n
                      \n
                    • Raport histopatologic care confirm\u0103 diagnosticul de cancer colorectal<\/li>\n
                    • Bilet de trimitere \/ recomandare medical\u0103<\/li>\n
                    • Date clinice relevante (stadializare, tratamente anterioare)<\/li>\n
                    • Rezultate imagistice disponibile (CT\/PET-CT\/RMN)<\/li>\n<\/ul>\n

                      Denumiri alternative<\/h3>\n
                        \n
                      • Colorectal Cancer Liquid Biopsy<\/li>\n
                      • Colon Cancer ctDNA Panel<\/li>\n
                      • Panel genetic somatic cancer colon<\/li>\n
                      • NGS Liquid Biopsy Colon Cancer<\/li>\n
                      • Colorectal ctDNA Testing<\/li>\n
                      • Liquid Biopsy Cancer de colon<\/li>\n
                      • Panel molecular cancer colorectal din s\u00e2nge<\/li>\n
                      • Colon Cancer Molecular Profiling<\/li>\n
                      • Somatic mutation panel colorectal<\/li>\n
                      • Biopsie lichid\u0103 cancer colorectal<\/li>\n<\/ul>\n

                        Particularit\u0103\u021bi ale testului<\/h3>\n

                        Acest test analizeaz\u0103 exclusiv muta\u021bii somatice (tumorale)<\/strong> \u0219i nu este destinat evalu\u0103rii predispozi\u021biei genetice ereditare la cancer colorectal. Pentru suspiciunea unui sindrom ereditar (ex. sindrom Lynch), se recomand\u0103 testare germinal\u0103 dedicat\u0103. Biopsia lichid\u0103 reprezint\u0103 un instrument esen\u021bial \u00een oncologia de precizie, oferind posibilitatea monitoriz\u0103rii continue a profilului molecular tumoral \u0219i adapt\u0103rii tratamentului \u00een timp real.<\/p>\n","protected":false},"excerpt":{"rendered":"

                        Panel genetic somatic realizat din biopsie lichid\u0103 (liquid biopsy)<\/strong>, destinat pacien\u021bilor cu cancer colorectal (colon \u0219i rect)<\/strong>, care analizeaz\u0103 ADN-ul tumoral circulant (ctDNA<\/strong>) din plasm\u0103 pentru identificarea muta\u021biilor genetice relevante clinic, utile \u00een alegerea terapiei \u021bintite \u0219i monitorizarea evolu\u021biei bolii.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"inline_featured_image":false},"product_brand":[],"product_cat":[1209,3165,2876],"product_tag":[],"class_list":["post-26806","product","type-product","status-publish","product_cat-analize","product_cat-oncogenetica","product_cat-serviciu-laborator","first","instock","sale","virtual","purchasable","product-type-simple"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t